Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 2/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 3/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
| ▸ | TTR | P02766 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11954968 | 0.93 | CYP4F2 (0.40) | POLBGAANPSR1PRKCACYP4F2 | |
| SCHEMBL26328701 | 0.91 | CYP4F2 (0.43) | POLBGAANPSR1PRKCACYP4F2 | |
| SCHEMBL1753756 | 0.86 | POLB (0.43) | POLBGAANPSR1PRKCACYP4F2 | |
| SCHEMBL27819169 | 0.85 | POLB (0.46) | POLBGAANPSR1PRKCACYP4F2 | |
| SCHEMBL7989588 | 0.85 | POLB (0.46) | POLBGAANPSR1PRKCACYP4F2 | |
| SCHEMBL29049106 | 0.83 | POLB (0.44) | POLBGAANPSR1PRKCACYP4F2 | |
| SCHEMBL16017798 | 0.83 | ADRA2A (0.37) | POLBGAANPSR1PRKCACYP4F2 | |
| SCHEMBL15223097 | 0.83 | POLB (0.34) | POLBGAANPSR1PRKCACYP4F2 | |
| SCHEMBL16641610 | 0.83 | CYP4F2 (0.32) | CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL21448666 | 0.83 | CYP4F2 (0.39) | POLBGAANPSR1PRKCACYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180153861-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-31 | — | — | US | disclosed |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-17 | — | — | US | disclosed |
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-11-23 | — | — | US | disclosed |
| US-20170274090-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-09-28 | — | — | US | disclosed |
| US-9629924-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2017-04-25 | — | — | US | disclosed |
| US-20160058873-A1 | Cyclodextrin-Based Polymers for Therapeutic Delivery | CERULEAN PHARMA INC (US) | 2016-03-03 | — | — | US | disclosed |
| US-20150209440-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20140328919-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20120302622-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | CERULEAN PHARMA INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120282306-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120225129-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | CERULEAN PHARMA INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. | 2012-08-23 | — | — | US | disclosed |
| US-20120052097-A1 | THERAPEUTIC PEPTIDE-POLYMER CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | CERULEAN PHARMA INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120041019-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20110268658-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2011-11-03 | — | — | US | disclosed |
| US-20110262490-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110237686-A1 | FORMULATIONS AND METHODS OF USE | CERULEAN PHARMA INC (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110189092-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170274090-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | POLB 230/4885GAA 971/4885NPSR1 3469/4885 |
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | POLB 230/4885GAA 971/4885NPSR1 3469/4885 |
| US-20160058873-A1 | Cyclodextrin-Based Polymers for Therapeutic Delivery | IAPP, PRCP, DDOST | POLB 3741/4885GAA 76/4885NPSR1 673/4885 |
| US-20120052097-A1 | THERAPEUTIC PEPTIDE-POLYMER CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | IAPP, PSAP, LNPEP | POLB 1780/4885GAA 194/4885NPSR1 312/4885 |
| US-20110268658-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | POLB 231/4885GAA 114/4885NPSR1 915/4885 |
| US-20120302622-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | SYNCRIP, EXOSC5, EXOSC9 | POLB 127/4885GAA 869/4885NPSR1 1363/4885 |
| US-20120041019-A1 | PROTEASE INHIBITORS | SERPINB1, PREP, DNPEP | POLB 1065/4885GAA 193/4885NPSR1 3816/4885 |
| US-20180153861-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | CETP, MTTP, APOB | POLB 3082/4885GAA 716/4885NPSR1 2348/4885 |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | POLB 230/4885GAA 971/4885NPSR1 3469/4885 |
| US-20110262490-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | POLB 231/4885GAA 114/4885NPSR1 915/4885 |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | POLB 2610/4885GAA 38/4885NPSR1 1355/4885 |
| US-20150209440-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CD44, DIS3, POLN | POLB 79/4885GAA 831/4885NPSR1 1110/4885 |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | POLB 2610/4885GAA 38/4885NPSR1 1355/4885 |
| US-20140328919-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | POLB 231/4885GAA 114/4885NPSR1 915/4885 |
| US-20120282306-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | POLB 231/4885GAA 114/4885NPSR1 915/4885 |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | POLB 230/4885GAA 971/4885NPSR1 3469/4885 |
| US-20110237686-A1 | FORMULATIONS AND METHODS OF USE | LPXN, LIPA, CHMP4B | POLB 3704/4885GAA 494/4885NPSR1 328/4885 |
| US-20110189092-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | POLB 231/4885GAA 114/4885NPSR1 915/4885 |
| US-20120225129-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | SYNCRIP, EXOSC5, EXOSC9 | POLB 127/4885GAA 869/4885NPSR1 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.